See also this year's filing and all EDGAR filings for this company.
PDF Report 0001157601_2023_MADRIGAL_PHARMACEUTICALS_INC.pdf
Logs
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.8249147159157746, 'aggregate_val': 542976000, 'exp_sum': 297535000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 48130000, 'ResearchAndDevelopmentExpense': 245441000, 'remainder_Expenses': 3964000}} |
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'Revenues', 'net_inc_node': 'NetIncomeLoss'} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001157601, MADRIGAL PHARMACEUTICALS INC.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 361,369,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 601,000 |
| 3 | remainder_Assets | 602,000 |
| 4 | LiabilitiesCurrent | 115,894,000 |
| 5 | LiabilitiesNoncurrent | 49,289,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 48,130,000 |
| 9 | ResearchAndDevelopmentExpense | 245,441,000 |
| 10 | remainder_Expenses | 249,405,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 2,185,000 |
| 13 | remainder_ComprehensiveNetIncome | 48,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 362,572,000 |
| 1 | Liabilities | 165,183,000 |
| 2 | Expenses | 542,976,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 197,389,000 |
| 5 | NetIncome | -540,791,000 |
| 6 | ComprehensiveNetIncome | -540,767,000 |
| 7 | BaseVar | 536,482,000 |
| 8 | EconomicCapitalRatio | -0.763 |
Edgar->Model Mapping
Feature Distribution
Change over Time
